Comera Life Sciences (CMRA) Competitors $0.0002 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends CMRA vs. SCPS, VAXX, EVLO, GNCA, ARDS, CALA, AMPE, CLVR, EFTR, and PXMDShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Scopus BioPharma Vaxxinity Evelo Biosciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics PaxMedica Comera Life Sciences (NASDAQ:CMRA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk. Does the MarketBeat Community believe in CMRA or SCPS? Scopus BioPharma received 2 more outperform votes than Comera Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformComera Life SciencesN/AN/AScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Does the media prefer CMRA or SCPS? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Scopus BioPharma Neutral Which has more volatility and risk, CMRA or SCPS? Comera Life Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Is CMRA or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has stronger earnings & valuation, CMRA or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$630K0.01-$18MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A SummaryComera Life Sciences and Scopus BioPharma tied by winning 2 of the 4 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6,000.00$7.05B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.9726.4919.17Price / Sales0.01268.58435.3770.93Price / CashN/A65.6738.0134.83Price / BookN/A6.707.644.62Net Income-$18M$138.76M$3.19B$246.06M7 Day PerformanceN/A-2.63%-2.12%-2.63%1 Month PerformanceN/A-2.33%-0.45%-2.16%1 Year PerformanceN/A-5.33%16.26%12.88% Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002SCPSScopus BioPharmaN/A$0.00flatN/A-91.7%$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090EVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5,000.00$3.09M0.0030CALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageAMPEAmpio PharmaceuticalsN/A$0.00-79.0%N/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoverageCLVRClever LeavesN/A$0.00-50.0%N/A-100.0%$2,000.00$17.42M0.00560Gap UpHigh Trading VolumeEFTReFFECTOR Therapeutics1.0633 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010PXMDPaxMedicaN/A$0.00-99.7%N/A-100.0%$1,000.00N/A0.002 Related Companies and Tools Related Companies SCPS Competitors VAXX Competitors EVLO Competitors GNCA Competitors ARDS Competitors CALA Competitors AMPE Competitors CLVR Competitors EFTR Competitors PXMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMRA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
